Talk:Tisagenlecleucel
| This is the talk page for discussing improvements to the Tisagenlecleucel article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Tisagenlecleucel.
|
Bach JAMA 2007
Here's a proper WP:MEDRS to add to the primary sources and press releases. Not only is this a good discussion of the price, it also clearly explains the technology.
https://jamanetwork.com/journals/jama/article-abstract/2654900
Viewpoint
November 21, 2017
FDA Approval of TisagenlecleucelPromise and Complexities of a $475 000 Cancer Drug
Peter B. Bach, MD1; Sergio A. Giralt, MD1; Leonard B. Saltz, MD1
JAMA. 2017;318(19):1861-1862. doi:10.1001/jama.2017.15218
--Nbauman (talk) 21:27, 25 November 2017 (UTC)
History Section Update
Suggest replacement of current final sentence which lacks citation with more accurate updated information.
Current: "The drug has been licensed to treat adults with diffuse large B-cell lymphoma (DLBCL), but as of September 2018 it had not been decided whether the NHS would use it.[citation needed]"
Replacement: "In March 2019 NICE issued guidance approving Kymriah for treatment of relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies.[1]
DonInUtah (talk) 03:09, 28 July 2021 (UTC)
I put this live as it replaces an uncited/outdated sentence with more accurate information from the UK government, and there was no commentary on the change. DonInUtah (talk) 19:10, 3 August 2021 (UTC)
References